FISH and Cytogenetic Testing in Blood Cancer — Reading Your Chromosomes to Guide Treatment

Cytogenetic testing in blood cancer is a group of lab tests that examine the chromosomes and genes inside your cells. Blood cancers often begin with a change in a chromosome, such as a missing piece, an extra copy or two chromosomes swapping sections. These tests find those changes. The main types are karyotyping, which photographs all 46 chromosomes, FISH, which uses glowing probes to light up specific genes, and molecular tests that read DNA directly. Together they confirm your exact diagnosis, sort your risk group and show whether a targeted drug may help. At CION, your treating doctor and our tumour board review every result before building your plan.

Both look at chromosomes, but in different ways. Karyotyping grows your cells in the lab, then photographs all 46 chromosomes to spot large changes across the whole genome. It gives a wide overview but is slower and can miss small changes. FISH, or Fluorescence In Situ Hybridisation, uses fluorescent probes that attach to one or a few specific genes and make them glow under the microscope. FISH is faster, often within a day or two, and more sensitive for known, important changes, even when only a few abnormal cells are present. In practice, the two are complementary. Karyotyping gives the big picture, while FISH confirms the specific genetic change that matters most for your disease.

Many blood cancers live mainly in the bone marrow, where blood cells are made. A bone marrow aspirate collects a small sample of marrow, usually from the back of the hip bone. This sample contains the cancer cells in their highest concentration, which gives the most accurate cytogenetic and FISH results. Sometimes a blood sample is enough, especially when abnormal cells circulate freely. The bone marrow procedure takes only a few minutes and is done with local anaesthesia to keep you comfortable. At CION, we try to collect everything we need from one procedure, so you are not called back for repeat sampling. Your doctor will explain exactly why a particular sample is needed for your case.

Turnaround depends on the test. FISH and many molecular tests are relatively fast, often giving results within one to a few days, because they target specific genes directly. Karyotyping takes longer, usually several days, because your cells must be grown in the lab before all 46 chromosomes can be photographed. Next-generation sequencing panels can take a little longer as they read many genes at once. Lab workload also affects timing. We understand the wait is stressful, so your CION care team will give you a realistic timeline for your specific tests and keep you updated. We never rush an interpretation, because an accurate result guides the right treatment for you.

Often, yes. Some blood cancers carry a specific gene change that has a drug designed to block it. The clearest example is the BCR-ABL1 gene fusion in chronic myeloid leukaemia, which can be treated with targeted tablets rather than broad chemotherapy alone. Other mutations, such as FLT3 in acute myeloid leukaemia, also have matched targeted options. Cytogenetic and molecular testing reveal whether your disease carries such a change. This can open a more precise, sometimes gentler treatment path. Not every blood cancer has a matched targeted drug, and we will always be honest about that. When a targeted option exists, testing is what unlocks it, which is why these tests can directly shape your treatment plan.

The Philadelphia chromosome is a well-known chromosome change found in chronic myeloid leukaemia and in some acute leukaemias. It forms when parts of chromosome 9 and chromosome 22 swap places, a process called a translocation. This swap creates an abnormal fused gene called BCR-ABL1, which drives the cancer cells to grow. Finding the Philadelphia chromosome, through karyotyping or FISH, confirms the diagnosis and is important because it points to specific targeted therapy. Tablets that block the BCR-ABL1 protein have transformed treatment for many patients with this change. Later, the same tests can measure how well treatment is working by tracking the level of the abnormal gene. This is a clear example of how one chromosome finding shapes the whole care plan.

You rarely need every test. Your haemato-oncologist chooses based on your suspected diagnosis and what will genuinely change your care. For some patients, a single FISH test confirms the key change and is enough. For others, a combination of karyotyping, FISH and a molecular panel gives the fullest picture. At CION, we follow a clear principle: no unnecessary tests. We order only what will help us diagnose accurately, sort your risk or guide treatment. You will know the cost of each test before it is done, with transparent pricing and no surprises. Decisions here are made for healing, not for billing. If a test will not change your plan, we will not put you through it.

Cytogenetic findings are one of the strongest guides to how a blood cancer is likely to behave. Some chromosome changes are linked with disease that responds well to standard treatment. Others suggest a higher-risk disease that may need a stronger or different approach. This is why doctors group patients into risk categories using these results. We want to be honest: prognosis depends on many factors, including your age, overall health, the disease type and how it responds to treatment, not chromosomes alone. We do not quote a fixed survival number, because every person is different. What we can promise is a clear, honest conversation about your risk group and what it means for your treatment and follow-up.

Sometimes, yes, and this is good news rather than a setback. The same tests that diagnosed your cancer can be repeated later to measure how deeply treatment has worked. For example, tracking the level of an abnormal gene like BCR-ABL1 shows whether it is falling, which tells us treatment is succeeding. This is called monitoring response or measuring minimal residual disease. It helps your doctor decide whether to continue, adjust or change therapy. Not every patient needs repeat testing, and the timing varies by disease. Your CION care team will explain whether monitoring applies to you and when. As always, we order repeat tests only when the result will guide a real decision in your care.

The cost depends on which tests you need, since karyotyping, FISH and molecular panels are priced differently. Because we order only the tests that will genuinely change your care, many patients need fewer tests than they expect. At CION, we believe in transparent costs. You will know the price of each recommended test before it is done, with no hidden charges and no unnecessary additions. Our decisions are made for your healing, not for billing. To get an accurate estimate for your specific situation, you can request a cost estimation or speak with our team, who will explain exactly what is advised and why. We are happy to give you a clear, written picture before you commit to anything.